LB Pharmaceuticals Inc

LB Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia and bipolar depression. Headquartered in New York, NY, the company aims to transform patient care by addressing significant unmet needs in these therapeutic areas.

The company's primary product candidate is LB-102, an oral small molecule designed as a novel benzamide antipsychotic. LB-102 is currently in late-stage clinical development, with a pivotal Phase 3 trial underway for acute schizophrenia and a Phase 2 trial initiated for bipolar depression. LB-102 is a methylated derivative of amisulpride, engineered to enhance blood-brain barrier penetration while maintaining receptor potency and selectivity.

LB Pharmaceuticals Inc. became publicly traded on Nasdaq under the ticker LBRX following an upsized initial public offering in September 2025. In January 2025, the company reported positive topline results from a Phase 2 trial of LB-102 in acute schizophrenia. More recently, in March 2026, LB Pharmaceuticals initiated its pivotal Phase 3 NOVA-2 trial for LB-102 in schizophrenia and a Phase 2 ILLUMINATE-1 trial for bipolar depression in January 2026. The leadership team includes Heather Turner, J.D., as Chief Executive Officer.